Responding to FDA, LabCorp Discontinues Offering OvaSure Test | GenomeWeb
NEW YORK (GenomeWeb News) – Responding to a recent warning letter from the US Food and Drug Administration regarding alleged “misbranding” of its OvaSure test, Laboratory Corporation of America said that it will discontinue offering the test and seek a meeting with the agency.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.